Abstract
There was a paradigm shift in the treatment of type 2 diabetes mellitus after 2015, which now implies not only the control and achievement of target levels of glycemia, but also takes into account the comorbidity of patients, the risks of MACE. The approach has become more individualized. In accordance with the consensus of 2022, patients with ASCVD, CKD, CHF are recommended to use at the start of therapy, in addition to lifestyle modification, metformin, drugs of the group of glucose-sodium co-transporter type 2 inhibitors with cardio- and nephroprotection.This article studied the efficacy of prescribing empagliflozin in addition to the already existing hypoglycemic therapy with metformin in a group of people in the amount of 30 people with morbid obesity, coronary artery disease, arterial hypertension for 12 months.Based on the results of the study, it was drawn that through the administration of empagliflozin, the following metabolic effects can be achieved: 1) achievement and maintenance of target levels of glycemia, 2) decrease in the level of glycated hemoglobin up to 1.7% maximum, 3) loss of weight, 4) improvement of the lipid profile.